transparent
FACE IPF HEAD ON and modify disease progression by slowing lung function decline

OFEV®(nintedanib) is a Recommended Treatment Option at Diagnosis for SSc-ILD Patients If Pharmacological Treatment is Required

01/23/2025 | Author: Boehringer Ingelheim
 

Document ID: PC-IME-100592 | Expiry Date: 09/13/2026

Related Product Item

Vault id: PC-IM-100592